Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| No statute on record | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 1 | 63.7% | +39.7% |
| BUNNER, BRIDGET E | 1 | 64.4% | +19.7% |
| DUFFY, BRADLEY | 1 | 54.4% | +45.4% |
| LUNDE, GRACE HENRY | 1 | 63.6% | +37.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 23d overdue |
| 18164952 | Covalent Diabodies and Uses Thereof | DUFFY, BRADLEY | 23d |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | BUNNER, BRIDGET E | 28d |
| 17787793 | Therapy for the Treatment of Cancer | LUNDE, GRACE HENRY | 34d |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1647 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 1643 | Other | Non-Final OA | 23d overdue | Pending | May 19, 2023 |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | BUNNER, BRIDGET E | 1647 | Other | Non-Final OA | 28d | Pending | Mar 06, 2023 |
| 18164952 | Covalent Diabodies and Uses Thereof | DUFFY, BRADLEY | 1643 | §103 | Non-Final OA | 23d | Pending | Feb 06, 2023 |
| 17787793 | Therapy for the Treatment of Cancer | LUNDE, GRACE HENRY | 1641 | Other | Final Rejection | 34d | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial